Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ESPR Esperion Therapeutics	$1.11 -5.1%	$0.99	$0.69 ▼ $3.94	$231.89M	0.7	4.82 million shs	2.92 million shs
KOD Kodiak Sciences	$3.71 -6.1%	$3.84	$1.92 ▼ $11.60	$208.42M	2.28	345,749 shs	178,424 shs
PROK ProKidney	$0.61 -4.8%	$0.77	$0.46 ▼ $2.59	$186.51M	1.26	702,533 shs	819,564 shs
RENB Renovaro	$0.30 +2.6%	$0.32	$0.27 ▼ $2.10	$49.72M	0.51	1.57 million shs	733,316 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ESPR Esperion Therapeutics	0.00%	+17.85%	-4.02%	-2.42%	-52.20%
KOD Kodiak Sciences	0.00%	+7.03%	-6.16%	+81.65%	+68.51%
PROK ProKidney	0.00%	+3.04%	-29.52%	+16.37%	-69.38%
RENB Renovaro	0.00%	-5.02%	-10.00%	-35.94%	-82.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ESPR Esperion Therapeutics	4.2201 of 5 stars	3.4	3.0	3.9	2.6	1.7	0.6
KOD Kodiak Sciences	4.1337 of 5 stars	3.0	4.0	4.6	1.1	3.3	0.0
PROK ProKidney	1.7933 of 5 stars	3.0	0.0	0.0	1.1	4.2	0.6
RENB Renovaro	1.1238 of 5 stars	0.0	2.0	0.0	2.5	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ESPR Esperion Therapeutics	2.80	Moderate Buy	$7.00	530.63% Upside
KOD Kodiak Sciences	2.00	Hold	$9.00	142.59% Upside
PROK ProKidney	2.00	Hold	$3.50	477.08% Upside
RENB Renovaro	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RENB, ESPR, PROK, and KOD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	PROK ProKidney	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00 ➝ $1.00
6/17/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/7/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $4.00
4/25/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/25/2025	ESPR Esperion Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/17/2025	ESPR Esperion Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$4.00 ➝ $3.00
4/8/2025	ESPR Esperion Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ESPR Esperion Therapeutics	$332.31M	0.66	$0.02 per share	48.70	($1.97) per share	-0.56
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	$2.86 per share	N/A
PROK ProKidney	$80K	2,219.03	N/A	N/A	($3.41) per share	-0.18
RENB Renovaro	N/A	N/A	N/A	N/A	$0.89 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ESPR Esperion Therapeutics	-$51.74M	-$0.80	N/A	N/A	N/A	-59.03%	-0.91%	-29.47%	8/11/2025 (Estimated)
KOD Kodiak Sciences	-$176.21M	-$3.63	N/A	N/A	N/A	N/A	-115.71%	-54.17%	8/13/2025 (Estimated)
PROK ProKidney	-$61.19M	-$0.60	N/A	N/A	N/A	N/A	N/A	-15.03%	8/8/2025 (Estimated)
RENB Renovaro	-$88.43M	-$0.77	N/A	∞	N/A	N/A	-60.38%	-47.04%	N/A

Latest RENB, ESPR, PROK, and KOD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KOD Kodiak Sciences	-$0.89	-$1.09	-$0.20	-$1.09	N/A	N/A
5/12/2025	Q1 2025	PROK ProKidney	-$0.16	-$0.13	+$0.03	-$0.13	N/A	$0.23 million
5/6/2025	Q1 2025	ESPR Esperion Therapeutics	-$0.18	-$0.21	-$0.03	-$0.21	$54.97 million	$65.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ESPR Esperion Therapeutics	N/A	N/A	N/A	N/A	N/A
KOD Kodiak Sciences	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A
RENB Renovaro	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ESPR Esperion Therapeutics	N/A	1.18	0.81
KOD Kodiak Sciences	N/A	4.62	4.62
PROK ProKidney	N/A	10.96	10.96
RENB Renovaro	N/A	0.13	0.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ESPR Esperion Therapeutics	47.39%
KOD Kodiak Sciences	89.06%
PROK ProKidney	51.59%
RENB Renovaro	71.41%

Insider Ownership

Company	Insider Ownership
ESPR Esperion Therapeutics	1.70%
KOD Kodiak Sciences	45.90%
PROK ProKidney	41.49%
RENB Renovaro	21.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ESPR Esperion Therapeutics	200	198.20 million	194.83 million	Optionable
KOD Kodiak Sciences	90	52.76 million	28.55 million	Optionable
PROK ProKidney	3	292.70 million	171.26 million	Optionable
RENB Renovaro	20	172.12 million	134.74 million	Optionable

RENB, ESPR, PROK, and KOD Headlines

Recent News About These Companies

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - Nasdaq

July 2, 2025 | nasdaq.com

Renovaro Biosciences: Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs - FinanzNachrichten.de

July 2, 2025 | finanznachrichten.de

Renovaro (NASDAQ:RENB) Stock Price Down 1.3% - Here's Why

July 1, 2025 | americanbankingnews.com

Renovaro (NASDAQ:RENB) Shares Down 1.3% - Time to Sell?

July 1, 2025 | marketbeat.com

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

June 30, 2025 | accessnewswire.comA

Renovaro subsidiary secures patent for drug discovery AI

June 5, 2025 | uk.investing.com

RENB-aandeel raakt 52-weeks dieptepunt van $ 0,27 door marktuitdagingen

June 5, 2025 | nl.investing.com

RENB stock touches 52-week low at $0.27 amid market challenges

June 5, 2025 | investing.com

Renovaro Obtains a U.S. Patent for its AI-Powered Platform for Medication Discovery and Diagnostics

June 5, 2025 | msn.com

Renovaro-dochter verkrijgt patent voor AI-gestuurde medicijnontwikkeling

June 3, 2025 | nl.investing.com

Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

June 3, 2025 | globenewswire.com

Renovaro Inc. Secures Ruling to Expedite Trial Against Predictive Oncology Over Breach of Merger Agreement

May 24, 2025 | nasdaq.com

Renovaro Inc. Accelerates 2025 Lawsuit to Force Predictive Oncology Merger

May 22, 2025 | insidermonkey.com

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 22, 2025 | globenewswire.com

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 22, 2025 | globenewswire.com

Renovaro partners with Amsterdam UMC on cancer diagnostics

May 15, 2025 | uk.investing.com

Renovaro lanceert AI-platform voor versnelling neurologische medicijnontwikkeling

May 15, 2025 | nl.investing.com

Renovaro Inc. and Amsterdam UMC Enter Exclusive Collaboration to Develop Blood Platelet RNA Diagnostics

May 15, 2025 | nasdaq.com

Renovaro launches AI platform to advance neurology drug discovery

May 15, 2025 | investing.com

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

May 14, 2025 | globenewswire.com

Renovaro gaat samenwerking aan met Amsterdam UMC voor kankerdiagnostiek

May 13, 2025 | nl.investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RENB, ESPR, PROK, and KOD Company Descriptions

Esperion Therapeutics NASDAQ:ESPR

$1.11 -0.06 (-5.13%)

Closing price 04:00 PM Eastern

Extended Trading

$1.12 +0.01 (+1.35%)

As of 07:59 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Kodiak Sciences NASDAQ:KOD

$3.71 -0.24 (-6.08%)

Closing price 04:00 PM Eastern

Extended Trading

$3.82 +0.12 (+3.10%)

As of 07:21 PM Eastern

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

ProKidney NASDAQ:PROK

$0.61 -0.03 (-4.82%)

Closing price 04:00 PM Eastern

Extended Trading

$0.61 +0.01 (+1.24%)

As of 07:38 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Renovaro NASDAQ:RENB

$0.30 +0.01 (+2.63%)

Closing price 04:00 PM Eastern

Extended Trading

$0.29 -0.01 (-2.53%)

As of 07:55 PM Eastern

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time